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Abstract
Visceral obesity and metabolic syndrome are commonly associated with non-alcoholic fatty liver disease (NAFLD). The
progression of steatosis to NASH depends on a number of metabolic and patient-related factors. The mechanisms of
genetic predisposition towards the development of NASH and related fibrosis remain unclear. In this study, our aim
was to utilize mitotyping and identify mitochondrial haplotypes that may be associated with NAFLD.
Methods: We examined mitochondrial haplotypes along with patatin-like phospholipase domain containing 3 (PNPLA3)
rs738409 genotype to determine their association with NAFLD phenotypes. Whole blood samples were obtained from 341
patients (BMI > 35) undergoing weight reduction surgery after written consent. Liver biopsies were centrally reviewed by a
single pathologist based on predetermined pathologic protocol (41.9 % Non-NASH NAFLD, 30.4 % NASH, 27.5 % controls).
A 1,122 bp of the mitochondrial control loop was sequenced for each sample and classified into haplogroups.
Results: The presence of haplogroup L exhibits protection against the development of NASH and pericellular
fibrosis. The alleles of PNPLA3 locus showed differential distribution in cohorts with NAFLD, NASH and pericellular
fibrosis. Heterozygosity at this locus is independently associated with higher risk of having NASH and pericellular fibrosis.
Conclusion: Mitochondrial genetics play an important role in NASH probably by modulation of oxidative stress and the
efficiency of oxidative phosphorylation.
Keywords: PNPLA3 rs738409, Hepatic fibrosis, Obesity, Ethnicity
Abbreviations: ALT, Alanine transaminase; AST, Aspartate aminotransferase; ATP, Adenosine triphosphate; BMI, Body
mass index; DNA, Deoxyribonucleic acids; HDL, High density lipoproteins; LDL, Low density lipoproteins; NAFLD, Non-
alcoholic fatty liver disease; NASH, Non-alcoholic steatohepatitis; PCR, Polymerase chain reaction; PNPLA3, patatin-like
phospholipase domain containing 3; ROS, Reactive oxygen species; SNP, Single nucleotide polymorphism
Background
Non-alcoholic fatty liver disease (NAFLD) is a leading
cause of chronic liver disease in the United States and
worldwide [1, 2]. The prevalence rate of NAFLD is
reported between 10 and 35 % in the general population
with the prevalence rates being substantially higher in
the obese and diabetic individuals [3].
NAFLD is characterized by accumulation of fat, mainly
triglycerides, in the absence of excessive alcohol con-
sumption, viral infection, hereditary disorders, or use of
steatogenic medications [4, 5]. In its progressive form,
NAFLD manifests as non-alcoholic steatohepatitis (NASH)
defined as steatosis with ballooning degeneration and/or
presence of Mallory-Denk bodies. NASH can ultimately
lead to fibrosis followed by cirrhosis and hepatocellular
carcinoma (HCC) [6–8].
Both visceral obesity and metabolic syndrome are
commonly associated with NASH [9]. However, not all
patients with NASH are obese [10]. The progression of
steatosis to NASH has been associated with a number of
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other metabolic factors, including the quality of nutrition
and patient’s lifestyle [11] as well as genetic predisposition
[12]. The mechanisms of genetic predisposition to the
development of NASH remain unclear, but certainly in-
volve the variation in individual susceptibility to NAFLD
[12]. A number of nuclear loci have already been identified
as potential contributors to development of NASH [13].
In 2008, a genome-wide association study in a popula-
tion comprising Hispanic, African American and Euro-
pean American subjects showed that a common genetic
variant in the patatin-like phospholipase domain con-
taining 3 protein (PNPLA3) gene is associated with liver
fat accumulation [14]. The isoleucine to methionine sub-
stitution at position 148 in the patatin-like phospholipase
domain containing 3 protein (PNPLA3; I148M variant,
rs738409) has since then been shown to be associated with
liver fat accumulation and severity of NAFLD [15–18].
The interaction between PNPLA3 and BMI has been sup-
ported by several population based studies [19–21]. The
studies have shown that body mass index interacts with
PNPLA3 and increases susceptibility to NAFLD. However,
PNPLA3 function and the effect of the I148M substitution
are not yet completely understood.
PNPLA3 protein plays anabolic and catabolic role in
lipid metabolism. Purified PNPLA3 protein has been
shown to have both hydrolase and lysophosphatidic acid
transacetylase activities, with the hydrolase activity pre-
dominating [22–24]. However, its in-vivo function and
physiological relevance remain controversial. In-vitro
studies have shown the 148 M mutation to be a loss-of-
function mutation abolishing the hydrolase activity [22,
24] while 148 M mutation is a gain of function mutation
for lysophosphatidic acid transacetylase (LPAAT) activity
[23]. Consistent with a hydrolase activity hypothesis, a
relative reduction in hepatic very low-density lipoprotein
secretion with the 148 M mutation has been shown in
vitro and in humans [25]. Contrary to the hydrolase ac-
tivity, wild-type PNPLA3 was also found to have lyso-
phosphatidic acid transacetylase activity and the 148 M
mutation was found to be a gain of function of the lipo-
genic activity [26]. In agreement, rats on a high-fat diet
treated with pnpla3 antisense oligonucleotides showed
decreased fatty acid esterification into hepatic triglycerides
and reduced insulin resistance [27]. In a recent study of
obese adolescents with hepatic steatosis, the I148M vari-
ant has been shown to modulate the association between
oxidized metabolites derived from linoleic acid and cyto-
keratin 18 fragment, a robust biomarker of liver injury
[28]. Recently, a cell specific PNPLA3 function linking
PNPLA3 to liver fibrosis has been shown [29, 30]. The
authors show retinyl-palmitate lipase activity of PNPLA3
in human hepatic stellate cells with I148M being a loss of
function mutation. Thus, the genotypic effect of PNPLA3
protein is complex.
In this study, our central hypothesis is that mitochon-
drial haplotypes along with a susceptible nuclear genetic
background may be involved in predisposing to NAFLD
and NASH. With this in mind, we examined mitochon-
drial haplotypes along with patatin-like phospholipase
domain containing 3 (PNPLA3) rs738409 genotype and
determined their association with NAFLD and NASH.
Methods
Patient cohort
After informed written consent, blood samples were ob-
tained from 341 patients (BMI > 35) undergoing weight
reduction surgery and immediately flash frozen in liquid
nitrogen followed by storage in −80 °C. All patients had
routine liver biopsies taken which were read by a central
pathologist. Clinical data from the time of enrollment
were collected and de-identified in compliance with
HIPAA regulations. This study has been approved by
Internal Review Board of Inova Fairfax Hospital (Federal
Assurance FWA00000573).
For the purpose of this study, metabolic syndrome
was defined by the presence of three or more of the
five following features: total cholesterol ≥200 mg/dl of
blood, LDL ≥130 mg/dl, triglyceride ≥150 mg/dl,
HDL < 50 mg/dl in women or less than 40 mg/dl in
men, and BMI >30. None of the included subjects
reported to have excessively consumed alcohol (>10 g/day
in women and >20 g/day in men) in the past 5 years.
Other chronic liver diseases were excluded by negative
serology for hepatitis B and C, no history of toxic expos-
ure and no other cause of chronic liver disease. Ethnicity
was recorded as self-reported.
Liver biopsy
Liver biopsies were centrally reviewed by a single path-
ologist based on predetermined grading system [31].
Histological features such as portal inflammation,
lymphoplasmacytic lobular inflammation, polymorpho-
nuclear lobular inflammation, Kupffer cell hypertrophy,
apoptotic bodies, focal parenchymal necrosis, glycogen
nuclei, hepatocellular ballooning, and Mallory-Denk
bodies were evaluated in the H & E sections. Steatosis
(Non-NASH NAFLD) was defined as fat with/without
lobular inflammation and/or portal inflammation. The
severity of steatosis was evaluated according to the per-
centage of liver parenchyma occupied by fat: 0 = none,
1 ≤ 5 %, 2 = 6–33 %, 3 = 34–66 %, and 4 > 66 %. Non-
alcoholic steatohepatitis (NASH) was defined as steato-
sis, lobular inflammation, and ballooning degeneration
with or without Mallory Denk bodies, and with or with-
out fibrosis. Severity of pericellular and portal fibrosis
was determined by Masson trichome staining of the bi-
opsy. The scoring was as follows: 0 = no fibrosis, 1 = mild
fibrosis, 2 = moderate fibrosis, 3 =marked fibrosis. A
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score of ≥ 3 was considered as advanced hepatic fibrosis
and a score of <3 as mild/no hepatic fibrosis. Patients
with hepatic steatosis or NASH were considered to have
NAFLD. Patients with normal liver histology were con-
sidered as controls.
Isolation of total DNA
Total DNA was extracted from whole blood cells using
QIAamp® kits in accordance with manufacturer’s instruc-
tions (Qiagen, USA). DNA was then quantified and quality
assessed by spectrophotometer (GeneQuant 1300, General
Electric). Additionally, to assess the integrity of extracted
DNA, agarose gel electrophoresis was carried out. The gel
was inspected for evidence of poor DNA quality visible as
degradation/smearing. Each DNA sample was diluted 1:10
prior to its use as PCR template.
Primer design and PCR
Amplification of the 1,122 base pair region of the mito-
chondrial control loop was achieved by using 4 pairs of
primers (Additional file 1: Table S1) with 100 basepair
overlap of resultant amplicons.
The PCR reaction was set up for 25 μl, containing
12.5 μl HotStar Taq Master Mix Kit (Qiagen®), 2.5 μl
(250 nM) of each primer, 1 μl of 1:10 diluted DNA, and
6.5 μl molecular grade water. The thermal cycling was as
follows: initial denaturation at 95 °C for 15 min; 30 cycles
of 95 °C for 1 min; annealing for 1 min; 72 °C for 1 min.
For sequencing, 20 μl of each PCR product was sent for
Sanger sequencing to GenScript (Piscataway, NJ).
Sequence assembly and mitochondrial haplotypes
identification
Chromatograms of forward and reverse fragments for each
primer pair were examined using Chromas Lite® (Techne-
lysium, Brisbane, Australia). The assembly and editing of
the fragments was carried out using Sequencher® (version
5.2.4), a consensus sequence of 1,122 bp of the mitochon-
drial control loop was generated for each DNA sample. All
DNA sequences were uploaded into MitoTool software
[32] and classified into 15 haplogroups. The success rate
of sequencing and subsequent alignment was 96 %.
PNPLA3 SNP rs738409 genotyping
Genotyping for the PNPLA3 SNP rs738409 was completed
using predesigned TaqMan probe (Applied Biosystems,
CA). Genotyping of rs738409 (C_7241_10) was carried out
on CFX96 PCR instrument (Biorad, USA) according to the
manufacturer’s protocol (50 °C for 2 min, 95 °C for
10 min, and then 40 cycles of 95 °C for 15 s and 60 °C for
1.5 min). After PCR amplification, a post-PCR plate reads
were carried out to generate allelic discrimination plot.
The allele assignments were independently verified by
RFLP analysis [33].
Statistical analysis
To assess the association of SNP rs738409 genotype and
mitochondrial haplotypes, a number of statistical proce-
dures were employed. The pairwise comparison cohorts
consisted of subjects with normal liver histology (con-
trols), Non-NASH NAFLD, NASH and NAFLD with
pericellular fibrosis. For continuous variables, p values
were determined by t-test and for categorical variables,
p values were determined by chi-square test. Linear
regression models were tested to assess the association
between genotype and continuous phenotypes, and
logistic regression models were used to test association
between genotype and categorical phenotype. Multi-
variate analysis was carried out to determine independ-
ent predictors of NAFLD.
Results
The clinical, demographic and biochemical characteristics
of study subjects (N = 341; BMI =48 ± 9.13, Age = 44 ±
11.2, 41.9 % Non-NASH NAFLD, 30.4 % NASH, 27.5 %
controls) are summarized in Table 1.
Patients with histologic NASH when compared to non-
NASH NAFLD had higher levels of serum aminotrans-
ferases compared to patients with non-NASH NAFLD
(p < 0.001) (Table 2). In contrast, fasting serum HDL and
platelets were lower in NASH patients compared to those
with non-NASH NAFLD (p < 0.001) (Table 2). Fasting
serum glucose, serum aminotransferases, serum triglycer-
ides and total cholesterol was higher, while serum HDL
and platelets were lower (p < 0.001) (Table 2) in patients
with Non-NASH NAFLD compared to controls with nor-
mal liver histology. Among the NASH and non-NASH
NAFLD subjects, there was no significant difference in the
mean BMI, age, serum triglycerides, serum cholesterol,
Table 1 Clinical and demographic characteristic of Study Cohort
Demographic/Clinical Variable Average ± SD or N (%)
Age (yrs) 44 ± 11.2
Males 88 (25 %)
BMI (kg/m2) 48 ± 9.13
ALT (U/L) 34.59 ± 25.9
AST (U/L) 26.37 ± 19.35
Glucose (mg/dl) 108.8 ± 36.76
Triglycerides (mg/dl) 157.9 ± 93.45
Total cholesterol (mg/dl) 187.69 ± 39.3
HDL (mg/dl) 47.28 ± 12.85
LDL (mg/dl) 108.2 ± 35.8
Normal liver biopsy 94 (27.5 %)
Non-NASH NAFLD 143 (41.9 %)
Histologic NASH 104 (30.4 %)
Continuous variables are represented as mean ± standard deviation (SD), and
categorical variables as percentages
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serum LDL and fasting glucose levels (p > 0.05) (Table 2).
Similarly, subjects with normal liver histology (controls)
had no significant difference in the mean BMI, WBC,
platelets, serum LDL and HDL levels when compared to
Non-NASH NAFLD subjects (p > 0.05) (Table 2). Notably,
patients with normal liver histology were more likely to be
younger and had higher platelets counts when compared
to those with NASH (p < 0.001) (Table 2).
Both NAFLD and NASH are associated with PNPLA3
rs738409 variants
In previous studies, PNPLA3 variant I148M (rs738409) has
been associated with both the obese phenotype and NAFLD.
In order to assess any potential interaction between PNPLA3
andmitochondrial DNA, we genotyped rs738409 in all of our
patients. The prevalence of the homozygous CC allele in study
population was 58 %, while GG allele frequency was 7.5 % and
GC allele frequency was 33.8 %. For the PNPLA3 SNP
rs738409 alleles, observed frequencies were in accordance
withHardy-Weinberg equilibrium [34–36].
In controls, the CC genotype of PNPLA3 rs738409
was more prevalent than in the NASH cohort (72.3 vs
43.3 %, p < 0.001). Similarly, the CC genotype was more
common in patients with non-NASH NAFLD as com-
pared to NASH (60.8 vs 43.3 %, p = 0.006), while the
prevalence GC genotype was higher in patients with
NASH as compared to those with Non-NASH NAFLD
(51.9 vs 25.5 %, p < 0.0001) and higher as compared with
the controls (51.9 vs 26.6 %, p = 0.0003). Interestingly, the
homozygosity for the risk allele (GG genotype) had higher
prevalence in Non-NASH NAFLD patients as compared
to NASH patients (14 vs 4.8 %, p = 0.018) (Fig. 1).
L mitochondrial haplogroup and NAFLD
In our study cohort, six common mitochondrial haplogroups
(H, L, U, K, J and T) had a prevalence of greater than 5 %. For
the purpose of further analysis, all the uncommon (<5 %)
haplotypes (A, C, I, W, M, N, X, B and R) were pooled to-
gether into one group (“Other”). Among the self-reported
ethnic groups, 77 % were White, 14.7 % were African
Americans, 3.5 %wereHispanic (Additional file 1: Figure S1).
The overall distribution of haplogroup lineages within
the self-identified race/ethnicity cohorts was in agreement
with a recent survey of haplogroups in United States [37].
For example, in self-identified population of whites,
European lineage haplogroups were the most common
haplogroup (35.5 %), with haplogroup H (41 %) being
the most common, followed by haplogroups U (17 %),
K (12 %), J (11 %) and T (9 %). These data are in agree-
ment with the H frequency reported recently to be 43 %
in non-hispanic whites of United States [37]. Among self-
identified African Americans, 91 % were confirmed as
being of African lineages (Fig. 2) with L2 (40 %) being the
most common haplogroup followed by L3 (36 %). Among
self-identified Hispanics, 70 % were confirmed as of
Asian/American Indian lineage (Fig. 2).
Table 2 Comparisons of Controls (normal liver histology) with Non-NASH NAFLD and NASH




NASH (N = 104) P-value* P-value† P-value‡
Age (yrs) 41.48 ± 10.86 44.08 ± 11.39 46.42 ± 10.94 0.0814 0.0017 0.1053
BMI (kg/m2) 46.80 ± 7.98 47.80 ± 8.50 49.47 ± 10.56 0.3733 0.0512 0.1715
WBC (x 103/uL) 7.81 ± 2.54 8.08 ± 2.21 8.82 ± 8.81 0.3784 0.2855 0.3366
Platelets (x 103/uL) 303.51 ± 69.73 291.01 ± 64.23 268.69 ± 66.97 0.1632 0.0005 0.0094
Insulin Resistance 1.92 ± 2.83 2.40 ± 1.18 8.37 ± 11.00 0.4879 0.0413 0.0154
Glucose (mg/dL) 94.16 ± 21.74 110.47 ± 36.20 120.22 ± 43.50 0.0002 <.0001 0.0641
ALT (U/L) 22.20 ± 9.74 31.58 ± 16.35 49.51 ± 37.25 <.0001 <.0001 <.0001
AST (U/L) 19.41 ± 5.57 23.49 ± 11.04 36.43 ± 29.69 0.0013 <.0001 <.0001
Triglycerides (mg/dL) 125.84 ± 58.42 160.26 ± 87.31 182.10 ± 117.04 0.0018 0.0001 0.1152
LDL (mg/dL) 100.96 ± 35.75 110.75 ± 35.40 111.71 ± 36.34 0.0620 0.0646 0.8555
Total cholesterol (mg/dL) 175.84 ± 34.00 193.24 ± 39.40 190.10 ± 41.96 0.0011 0.0150 0.5683
HDL (mg/dL) 50.40 ± 12.42 48.58 ± 13.63 42.68 ± 10.96 0.3461 <.0001 0.0014
White: N (%) 66 (70.2 %) 112 (78.3 %) 84 (80.8 %) 0.1579 0.0835 0.6389
Diabetes: N (%) 17 (18.3 %) 44 (30.8 %) 46 (44.2 %) 0.0322 <.0001 0.030
Hyperlipidemia: N (%) 34 (37.4 %) 69 (50.0 %) 59 (59.6 %) 0.0599 0.0022 0.1438
Hypertension: N (%) 40 (44.4 %) 81 (57.9 %) 64 (65.3 %) 0.0468 0.0041 0.2464
Sleep Apnea: N (%) 53 (57.6 %) 100 (71.9 %) 81 (80.2 %) 0.0241 0.0007 0.1425
*Pairwise comparison between controls (normal liver histology) and Non-NASH NAFLD cohorts; †Pairwise comparison between controls (normal liver histology)
and NASH cohorts; ‡Pairwise comparison between Non-NASH NAFLD and NASH cohorts. Continuous variables are represented as mean ± standard deviation (SD),
and categorical variables as percentages. For convenience, all statistically significant p-values are highlighted by bold font
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Mitochondrial haplogroup assessment showed that
African lineage Haplogroup L (encompasses L0, L1, L2
and L3 subtypes) was less prevalent in Non-NASH
NAFLD and NASH cohorts as compared to the cohort
with normal liver histology, p < 0.018 and p < 0.0002,
respectively. This suggests that L haplogroup may pro-
tect against NAFLD (Table 3).
Nuclear and mitochondrial genotypes as NASH predictors
An initial univariate analysis showed that in population
of patients with NAFLD (N = 247), the heterozygosity
for PNPLA3 rs738409 variant may serve as independent
predictor of having histologic NASH (OR 2.9: 95 % CI
1.67 – 5.05). When similar analyses were performed for
mitochondrial haplogroups, only L haplogroup provided
protection against histologic NASH (OR 0.34: 95 % CI
0.13 – 0.86) (Table 4).
In non-L haplotype cohort, further multivariate ana-
lysis after adjusting for gender, age and ALT showed that
patients with GC genotype of PNPLA3 locus are twice
more likely to have NASH as compared to those with
genotype CC (OR 2.66: 95 % CI 1.43 – 4.95).
Nuclear and mitochondrial genotypes in pericellular fibrosis
Since fibrosis is an important predictor of clinical out-
come, we assessed the association between mitochondrial
haplogroups and PNPLA3 genotype with pericellular
fibrosis as well as with other histologically features.
Fig. 2 Haplogroup distribution by self-identified ethnicity in our study population. European lineages: H, T, U, V, X, K, N, I, J, HV, W; African
Lineages: L, L1, L2, L3, L3; Asian/American Indian: A, B, F, macro-haplogroup M (C, D, E, and G), X
Fig. 1 The prevalence of PNPLA3 rs738409 variant in NASH, Non-NASH NAFLD and Normal Liver Histology cohorts (p < 0.05 significant).
* Significant pair-wise comparison between controls with normal liver histology and NASH; + Significant pair-wise comparison between
Non-NASH NAFLD and NASH; x Significant pair-wise comparison between controls with normal liver histology and Non-NASH NAFLD
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Table 3 Distribution of mitochondrial haplotypes in study groups






P value* P-value† P value‡
Haplotype
H 28 (29.8 %) 56 (39.2 %) 37 (35.6 %) 0.1400 0.3863 0.5660
L 23 (24.5 %) 22 (15.4 %) 6 (5.8 %) 0.0811 0.0002 0.0186
U 11 (11.7 %) 14 (9.8 %) 17 (16.3 %) 0.6393 0.3490 0.1247
K 8 (8.5 %) 12 (8.4 %) 11 (10.6 %) 0.9743 0.6221 0.5595
J 11 (11.7 %) 11 (7.7 %) 5 (4.8 %) 0.2980 0.0755 0.3631
T 6 (6.4 %) 9 (6.3 %) 6 (5.8 %) 0.9780 0.8566 0.8647
Other 4 (4.3 %) 13 (9.1 %) 18 (17.3 %) 0.1582 0.0035 0.0543
*Pairwise comparison between controls (normal liver histology) and Non-NASH NAFLD cohorts; †Pairwise comparison between controls (normal liver histology)
and NASH cohorts; ‡Pairwise comparison between Non-NASH NAFLD and NASH cohorts. For convenience, significant p-values are highlighted by bold font
Table 4 Univariate-adjusted analysis for NASH vs Non-NASH NAFLD
Variable Name Sample Size P Value Odds Ratio Lower OR Upper OR
Age (yrs) 247 0.106 1.02 1.00 1.04
BMI (kg/m2) 244 0.173 1.02 0.99 1.05
WBC (x 103/uL) 246 0.396 1.02 0.97 1.08
Platelet (x 103/ul) 242 0.011 0.99 0.99 1.00
IR (HOMA) 40 0.009 2.20 1.22 3.97
Glucose (mg/dL) 232 0.068 1.01 1.00 1.01
ALT (U/L) 245 0.000 1.03 1.02 1.05
AST (U/L) 245 0.000 1.05 1.03 1.08
Triglycerides (mg/dL) 219 0.127 1.00 1.00 1.01
LDL (mg/dL) 193 0.854 1.00 0.99 1.01
Total Cholesterol (mg/dL) 223 0.567 1.00 0.99 1.00
HDL (mg/dL) 198 0.002 0.96 0.94 0.99
Male 247 0.000 4.47 2.48 8.06
White 247 0.639 1.16 0.62 2.18
Diabetes 247 0.031 1.78 1.06 3.02
Hyperlipidemia 237 0.144 1.47 0.88 2.49
Hypertension 238 0.247 1.37 0.80 2.34
Haplotype,
H 247 0.566 0.86 0.51 1.45
L 247 0.023 0.34 0.13 0.86
U 247 0.128 1.80 0.84 3.84
Other 247 0.058 2.09 0.98 4.49
K 247 0.560 1.29 0.55 3.05
J 247 0.367 0.61 0.20 1.80
T 247 0.866 0.91 0.31 2.65
PNPLA3 SNP,
CC Reference
GC 247 0.000 2.90 1.67 5.05
GG 247 0.172 0.48 0.17 1.37
For convenience, significant p-values are highlighted by bold font
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NAFLD patients without pericellular fibrosis (N = 247)
had higher platelet and serum HDL levels (Table 5) com-
pared to those with pericellular fibrosis (N = 95). Serum
aminotransferases were lower in these subjects compared
to those with pericellular fibrosis. Notably, NAFLD pa-
tients with pericellular fibrosis were enriched for L hap-
logroup (L0, L1, L2, L3) (15.8 vs 4.2 %, p = 0.005),
compared to NAFLD patients without pericellular fibrosis.
Homozygous genotypes for PNPLA3: CC and GG,
were more prevalent in NAFLD patients without pericel-
lular fibrosis (61.8 vs 40 % for CC, p = 0.0008 and 13.2
vs 5.3 %, p = 0.04). However, the association of GG geno-
type with pericellular fibrosis should be considered with
caution due to the small sample size of GG genotype.
GC genotype, on the other hand was more common in
pericellular fibrosis cohort (54.7 vs 25 %, p < 0.001).
Univariate analysis revealed that L haplotype was protective
against odds of developing pericellular fibrosis (OR 0.23: 95 %
CI 0.08–0.70) and patients with heterozygosity in PNPLA3
locus had a 3 times higher odds of developing pericellular fi-
brosis as compared to patients CC genotype (OR 3.39: 95 %CI
1.93– 5.94) (Table 6). After adjusting for age, number of plate-
lets, levels of ALT, AST, triglycerides, HDL and male gender,
individuals with PNPLA3 GC genotype remained associated
with higher likelihood of having pericellular fibrosis than those
with PNPLA3 genotype CC (OR 4.38: 95%CI 2.17– 8.85).
Discussion
Oxidative stress is an important player in development
of progressive NAFLD or NASH. In fact, oxidative stress
related cellular damage, reflected as hepatic necrosis or
apoptosis, is a mitochondrial dependent factor that po-
tentially influences the progression of NAFLD [38–40].
Given that mitochondria are critical players in maintain-
ing balance of energy input and expenditure [41] as well
as the pathogenesis of NASH, it is enticing to explore
Table 5 Comparisons of NAFLD patients with pericellular fibrosis with NAFLD patients without pericellular fibrosis
Variable NAFLD without NAFLD with P-value
p. fibrosis (N = 152) p. fibrosis (N = 95)
Age (yrs) 44.03 ± 11.08 46.73 ± 11.35 0.0609
BMI (kg/m2) 48.05 ± 8.94 49.23 ± 10.19 0.1752
WBC (x 103/uL) 8.16 ± 2.35 8.77 ± 9.15 0.5668
Platelets (x 103/uL) 290.32 ± 63.79 267.63 ± 67.91 0.0094
Insulin Resistance 2.42 ± 1.16 8.69 ± 11.25 0.0009
Glucose (mg/dL) 111.01 ± 36.85 120.25 ± 43.34 0.2630
ALT (U/L) 32.38 ± 17.62 49.95 ± 37.96 <.0001
AST (U/L) 23.97 ± 11.78 36.88 ± 30.51 <.0001
Triglycerides (mg/dL) 159.48 ± 86.89 185.17 ± 119.26 0.0760
LDL (mg/dL) 112.12 ± 36.03 109.52 ± 35.33 0.7968
Total cholesterol (mg/dL) 193.96 ± 39.81 188.62 ± 41.43 0.3486
HDL (mg/dL) 48.38 ± 13.47 42.69 ± 11.20 0.0004
Male: N (%) 26 (17.1 %) 45 (47.4 %) <.0001
White: N (%) 119 (78.3 %) 77 (81.1 %) 0.6017
HAPLOTYPE, N (%)
H 58 (38.2 %) 35 (36.8 %) 0.8355
L 24 (15.8 %) 4 (4.2 %) 0.0052
U 17 (11.2 %) 14 (14.7 %) 0.4123
Other 13 (8.6 %) 18 (18.9 %) 0.0164
K 12 (7.9 %) 11 (11.6 %) 0.3324
J 11 (7.2 %) 5 (5.3 %) 0.5398
T 10 (6.6 %) 5 (5.3 %) 0.6736
PNPLA3_SNP, N (%)
CC 94 (61.8 %) 38 (40.0 %) 0.0008
GC 38 (25.0 %) 52 (54.7 %) <0.0001
GG 20 (13.2 %) 5 (5.3 %) 0.0454
For convenience, significant p-values are highlighted by bold font
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mitochondrial genome variation as a potential genetic fac-
tor that could contribute to the pathogenesis of NASH.
Mitochondria have their own circular DNA that can be cat-
egorized into various haplogroups based on variants within its
non-coding hypervariable region. Notably, the non-coding re-
gion is indispensable for replication and transcription of the
mitochondrial genome. Thus variations in this region are ex-
pected to influence the ability of mitochondria to produce
ATP and ROS. In turn, availability of ATP and the production
of ROS are known to affect tissue responses to extrinsic or in-
trinsic stressors and energy demands. Consequently, mito-
chondrial DNA variations have been the focus of studies in
patients with altered metabolism [42–44]. Additionally, in a
recent study, there is evidence that mitochondrial DNA hap-
logroups may influence expression of nuclear genes that are
induced under oxidative stress [45].
NAFLD is a complex disease with genetic and environ-
mental factors interacting to influence the development
and progression of the disease. The relative importance of
these factors may vary between populations depending on
genetic background and lifestyle. This study is unique as we
show for the first time the differential prevalence of mito-
chondrial haplogroups in obese patients (BMI > 35)
with varying severity of NAFLD. We also examine the
interaction between mitochondrial genome variation
and nuclear PNPLA3 genotype in this patient cohort.
In this study, we present evidence that mitochondrial
haplogroup L is less prevalent in subjects with NASH
and may thus be protective against NASH (Table 3).
Haplogroup L has the highest sequence divergence from
other haplogroups [46]. A recent study demonstrated
that L haplogroup is also functionally different [45].
Table 6 Univariate-adjusted analysis for Pericellular fibrosis
Variable Name Sample Size P Value Odds Ratio Lower OR Upper OR
Age (yrs) 247 0.067 1.02 1.00 1.05
BMI (kg/m2) 244 0.345 1.01 0.99 1.04
WBC (x 103/uL) 246 0.467 1.02 0.97 1.07
Platelet (x 103/ul) 242 0.011 0.99 0.99 1.00
IR (HOMA) 40 0.008 2.26 1.24 4.14
Glucose (mg/dL) 232 0.087 1.01 1.00 1.01
ALT (U/L) 245 0.000 1.03 1.01 1.04
AST (U/L) 245 0.000 1.05 1.02 1.07
Triglycerides (mg/dL) 219 0.080 1.00 1.00 1.01
LDL (mg/dL) 193 0.623 1.00 0.99 1.01
Total Cholesterol (mg/dL) 223 0.338 1.00 0.99 1.00
HDL (mg/dL) 198 0.003 0.96 0.94 0.99
Male 247 0.000 4.36 2.43 7.82
White 247 0.602 1.19 0.62 2.25
Diabetes 247 0.011 1.99 1.17 3.38
Hyperlipidemia 237 0.012 1.99 1.16 3.42
Hypertension 238 0.254 1.37 0.80 2.36
Haplotype
H 247 0.836 0.95 0.56 1.61
L 247 0.009 0.23 0.08 0.70
U 247 0.414 1.37 0.64 2.93
Other 247 0.019 2.50 1.16 5.38
K 247 0.335 1.53 0.65 3.62
J 247 0.541 0.71 0.24 2.12
T 247 0.674 0.79 0.26 2.38
PNPLA3_SNP
CC Reference
GC 247 0.000 3.39 1.93 5.94
GG 247 0.370 0.62 0.22 1.77
For convenience, significant p-values are highlighted by bold font
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When compared to the cybrids with H haplogroup,
those with L haplogroup demonstrated lower levels of
the ROS production but similar levels of ATP generation,
indicative of more efficient oxidative phosphorylation with
lower electron leakage and higher efficiency of aerobic res-
piration [45]. These observations support the hypothesis
that the patients with L haplogroup may be intrinsically
protected from oxidative stress and thus, potential liver
damage by ROS.
It is also important to note that the mitochondrial
haplogroups are commonly used as a proxy to ethnic
origin of individual. According to the population-based
studies, NAFLD and NASH are more prevalent in indi-
viduals of Hispanic origin [3, 47], while African Ameri-
cans are somewhat protected against high prevalence of
NAFLD and NASH [48]. The high prevalence of L hap-
logroup in subjects of African origin may serve as a
physiological explanation for this phenomenon, although
further studies will be needed to determine the causality.
In our study cohort, 88 % (N = 44) of the self-reported
African Americans had L haplotype and 66 % (N = 33) of
them had normal liver biopsy, 22 % (N = 11) had steato-
sis and 12 % (N = 6) had NASH. Additional studies with
a larger African American cohort will be needed to fur-
ther validate this trend. Notably, the haplotype results of
our study are consistent with the haplogroup propor-
tions reported in a recent large population based study
in United States [37].
In addition to mitochondrial haplotypes, we also mea-
sured the well-described gene PNPLA3 variant rs738409
associated with NAFLD. The rs738409 variant is located in
coding region of PNPLA3 gene. This variant corresponds
to Isoleucine to Methionine substitution (p.I148M) and
has previously been identified as risk factor for steatohepa-
titis, NAFLD-cirrhosis [14, 49] and hepatocellular carcin-
oma [15, 20, 50–52]. The 148 M variant has also been
linked to elevated aminotransferase levels [53] and liver fi-
brosis [54]. However, the effect of the I148M substitution
on the functioning of PNPLA3 is still enigmatic [15]. The
148 M variation is reported to result in loss of hydrolase
activity (loss-of-function model) [22, 24, 55] and thus
cause accumulation of triglyceride in the liver. However,
studies in knock-out mice show contrary results [26, 56].
These studies show that loss of PNPLA3 hydrolase activ-
ity does not alter hepatic triglycerides. PNPLA3 variant
has also been shown to have a gain of lysophosphatidic
acid transacetylase (LPAAT) activity. The 148 M substi-
tution increases LPAAT activity and results in increased
TAG synthesis (gain-of-function model) [15, 23]. Thus,
PNPLA3 148 M variant may increase hepatic triglyceride
levels by multiple changes in triglyceride metabolism.
Our results with regards to PNPLA3 are in agreement
with the previously reported studies. The alleles of PNPLA3
locus showed differential distribution in cohorts with
NAFLD, NASH (Table 2) and pericellular fibrosis. More-
over, multivariate analysis showed that heterozygosity in
this locus is independently associated with higher risk of
having NASH as well as with pericellular fibrosis. Over-
all, carrying G allele in position rs738409 appears to
increase the odds of developing NASH and pericellular
fibrosis. Importantly, in the final multivariate model of
NAFLD (Table 4), no interaction between the nuclear
rs738409 variant and mitochondrial haplogroup was
detected. This indicates that the somatic genotype
and mitochondrial genotype can have independent
and important impact in the pathogenesis of NASH.
Conclusion
In conclusion, our data shows that the presence of hap-
logroup L exhibits certain degree of protection against
the development of NASH and pericellular fibrosis. This
suggests that, besides nuclear genome variants and
environmental factors, the mitochondrial genetics may
play an important role in NAFLD probably by modula-
tion of oxidative stress and the efficiency of oxidative
phosphorylation. Further studies will be needed to
confirm the causality. Moreover, United States cohorts
are substantially admixed, resulting in ambiguity in the
questionnaire-based ethnicity assessments [57]. Thus,
ethnicity verifying mitochondrial haplogroup data should
be coupled with the other biomarkers to serve as a
valuable resource for future studies investigating NAFLD
and NASH in such populations.
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